Literature DB >> 19177330

Demonstration of 1-year duration of immunity for attenuated Bordetella bronchiseptica vaccines in dogs.

Craig Lehar1, Huchappa Jayappa, Jason Erskine, Alicia Brown, Diane Sweeney, Terri Wassmoen.   

Abstract

Three groups of healthy dogs with low antibody titers to Bordetella bronchiseptica (Bb), canine parainfluenza virus (CPI), and canine adenovirus type 2 (CAV-2) were used in this study. One group was vaccinated with a single dose of monovalent attenuated Bb vaccine and one group with a trivalent vaccine containing attenuated Bb, CPI, and CAV-2; dogs were vaccinated intranasally with a single dose of the respective vaccines. The third group served as unvaccinated controls. All vaccinated dogs subsequently developed serum antibody titers to Bb that persisted for at least 1 year. Following Bb challenge 1 year after vaccination, all vaccinated dogs, regardless of group, showed significantly fewer clinical signs and shed significantly fewer challenge organisms than unvaccinated controls. These results demonstrate that intranasal administration of a single dose of monovalent attenuated Bb vaccine or trivalent vaccine containing attenuated Bb, CPI, and CAV-2 provides 1 year of protection against Bb.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19177330

Source DB:  PubMed          Journal:  Vet Ther        ISSN: 1528-3593


  4 in total

1.  Effects of Intranasal and Oral Bordetella bronchiseptica Vaccination on the Behavioral and Olfactory Capabilities of Detection Dogs.

Authors:  Amanda Collins; Rachel A Bear; Amritha Mallikarjun; Sarah A Kane; Jennifer L Essler; Patricia Kaynaroglu; Rebecca Feuer; Jordan G Smith; Cynthia M Otto
Journal:  Front Vet Sci       Date:  2022-05-18

2.  Thirteen-month duration of immunity of an oral canine vaccine against challenge with Bordetella bronchiseptica.

Authors:  Maya Scott-Garrard; Xinshuo Wang; Yu-Wei Chiang; Frederic David
Journal:  Vet Rec Open       Date:  2020-10-16

Review 3.  The challenges in developing effective canine infectious respiratory disease vaccines.

Authors:  Judy A Mitchell; Joe Brownlie
Journal:  J Pharm Pharmacol       Date:  2015-03-03       Impact factor: 3.765

4.  A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers.

Authors:  Rigmor Thorstensson; Birger Trollfors; Nabil Al-Tawil; Maja Jahnmatz; Jakob Bergström; Margaretha Ljungman; Anna Törner; Lena Wehlin; Annie Van Broekhoven; Fons Bosman; Anne-Sophie Debrie; Nathalie Mielcarek; Camille Locht
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.